Premium
Effect of serum blocking factors on leukocyte adherence inhibition in breast cancer patients. Specificity and correlation with tumor burden
Author(s) -
Yonemoto Robert H.,
Fujisawa Takehiko,
Waldman Stephen R.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197804)41:4<1289::aid-cncr2820410412>3.0.co;2-u
Subject(s) - medicine , breast cancer , cancer , blocking (statistics) , oncology , correlation , immunology , statistics , geometry , mathematics
Serum blocking factors (SBF) were examined in 78 sera obtained from 64 breast cancer patients, 25 sera obtained from normal donors and 18 sera obtained from patients with other types of recurrent cancers, by employing leukocyte adherence inhibition (LAI) assay. SBF was demonstrated in 41 out of 78 sera obtained from breast cancer patients. However, SBF was not demonstrated in patients with other cancers and demonstrated in only 1 out of 25 normal donors. This difference was significant (p < 0.005). Sera from 24 out of 36 breast cancer patients with recurrent disease and sera from 6 out of 13 breast cancer patients with local tumor or regional involvement demonstrated SBF. However, only sera from 5 out of 22 breast cancer patients with clinically no evidence of disease (NED) demonstrated SBF. This was significantly different from patients with recurrence (p < 0.005). When SBF and clinical stage were studied, stages 1 and 2 were significantly different from stage 3 (p < 0.025). Blocking index of sera obtained from patients with positive LAI and preincubated with autologous leukocytes was 1.12 ± 0.11 and blocking index of sera obtained from patients with negative LAI and preincubated with allogeneic leukocytes with positive LAI was 0.56 ± 0.14. This difference was significant (p < 0.005). Our results suggest that SBF correlates with tumor burden and clinical stage and SBF directed to “semi‐private” antigenic determinants may play an important role in blocking of cell mediated immunity (CMI) directed to tumor associated antigens (TAA) in this assay.